Long-term survival analysis of masitinib in amyotrophic lateral sclerosis

Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in neurological disorders Vol. 14; p. 17562864211030365
Main Authors Mora, Jesus S., Bradley, Walter G., Chaverri, Delia, Hernández-Barral, María, Mascias, Javier, Gamez, Josep, Gargiulo-Monachelli, Gisella M., Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Ludolph, Albert C.
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 2021
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects
Online AccessGet full text
ISSN1756-2864
1756-2856
1756-2864
DOI10.1177/17562864211030365

Cover

Abstract Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001. Methods: Survival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity. Results: A significant survival benefit of 25 months (p = 0.037) and 47% reduced risk of death (p = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib (n = 45) versus placebo (n = 62) in an enriched cohort with ⩾2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 versus 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31–0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001. Conclusions: Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality. This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).
AbstractList Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001. Methods: Survival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity. Results: A significant survival benefit of 25 months ( p  = 0.037) and 47% reduced risk of death ( p  = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib ( n  = 45) versus placebo ( n  = 62) in an enriched cohort with ⩾2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 versus 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31–0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001. Conclusions: Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality. This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).
A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001. Survival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity. A significant survival benefit of 25 months (  = 0.037) and 47% reduced risk of death (  = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib (  = 45) placebo (  = 62) in an enriched cohort with ⩾2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31-0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001. Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality.This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).
Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001. Methods: Survival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity. Results: A significant survival benefit of 25 months (p = 0.037) and 47% reduced risk of death (p = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib (n = 45) versus placebo (n = 62) in an enriched cohort with ⩾2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 versus 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31–0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001. Conclusions: Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality. This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).
A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001.BACKGROUNDA randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate from disease onset to baseline of <1.1 points/month. Here we assess long-term overall survival (OS) data of all participants from study AB10015 and test whether a signal in OS is evident in an enriched patient population similar to that prospectively defined for confirmatory study AB19001.Survival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity.METHODSSurvival status of all patients originally randomized in AB10015 was collected from participating investigational sites. Survival analysis (using the multivariate log-rank test and Cox proportional hazards model, with stratification factors as covariates) was performed on the intention-to-treat population and enriched subgroups, which were defined according to initial randomization, baseline ALSFRS-R progression rate and baseline disease severity.A significant survival benefit of 25 months (p = 0.037) and 47% reduced risk of death (p = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib (n = 45) versus placebo (n = 62) in an enriched cohort with ⩾2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 versus 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31-0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001.RESULTSA significant survival benefit of 25 months (p = 0.037) and 47% reduced risk of death (p = 0.025) was observed for patients receiving 4.5 mg/kg/day masitinib (n = 45) versus placebo (n = 62) in an enriched cohort with ⩾2 on each baseline ALSFRS-R individual component score (i.e. prior to any complete loss or severe impairment of functionality) and post-onset ALSFRS-R progression rate <1.1 (i.e. exclusion of very fast progressors) [median OS of 69 versus 44 months, respectively; hazard ratio, 0.53 [95% CI (0.31-0.92)]]. This corresponds to the population enrolled in confirmatory phase III study, AB19001.Analysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality.This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).CONCLUSIONSAnalysis of long-term OS (75 months average follow-up from diagnosis) indicates that oral masitinib (4.5 mg/kg/day) could prolong survival by over 2 years as compared with placebo, provided that treatment starts prior to severe impairment of functionality.This trial was registered at www.ClinicalTrials.gov under identifier NCT02588677 (28 October 2015).
Author Gargiulo-Monachelli, Gisella M.
Moussy, Alain
Hernández-Barral, María
Mascias, Javier
Ludolph, Albert C.
Mansfield, Colin D.
Gamez, Josep
Bradley, Walter G.
Chaverri, Delia
Mora, Jesus S.
Hermine, Olivier
Author_xml – sequence: 1
  givenname: Jesus S.
  surname: Mora
  fullname: Mora, Jesus S.
  organization: ALS Unit, Hospital San Rafael, Madrid, Spain
– sequence: 2
  givenname: Walter G.
  surname: Bradley
  fullname: Bradley, Walter G.
  organization: Department of Neurology, University of Miami School of Medicine, Miami, FL, USA
– sequence: 3
  givenname: Delia
  surname: Chaverri
  fullname: Chaverri, Delia
  organization: ALS Unit, Department of Neurology, University Hospital La Paz-Carlos III, Madrid, Spain
– sequence: 4
  givenname: María
  surname: Hernández-Barral
  fullname: Hernández-Barral, María
  organization: ALS Unit, Department of Neurology, University Hospital La Paz-Carlos III, Madrid, Spain
– sequence: 5
  givenname: Javier
  surname: Mascias
  fullname: Mascias, Javier
  organization: ALS Unit, Department of Neurology, University Hospital La Paz-Carlos III, Madrid, Spain
– sequence: 6
  givenname: Josep
  orcidid: 0000-0003-3127-7486
  surname: Gamez
  fullname: Gamez, Josep
  organization: Neurology Department, GMA Clinic, Autonomous University of Barcelona, European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD), Barcelona, Spain
– sequence: 7
  givenname: Gisella M.
  surname: Gargiulo-Monachelli
  fullname: Gargiulo-Monachelli, Gisella M.
  organization: Hospital Universitario CEMIC-CONICET Buenos Aires, Argentina
– sequence: 8
  givenname: Alain
  surname: Moussy
  fullname: Moussy, Alain
  organization: AB Science, Paris, France
– sequence: 9
  givenname: Colin D.
  orcidid: 0000-0001-9175-5051
  surname: Mansfield
  fullname: Mansfield, Colin D.
  organization: AB Science, Paris, France
– sequence: 10
  givenname: Olivier
  surname: Hermine
  fullname: Hermine, Olivier
  email: ohermine@gmail.com
  organization: Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implication, Imagine Institute, INSERM UMR 1163 and CNRS ERL 8254, Hôpital Necker, Paris, France
– sequence: 11
  givenname: Albert C.
  surname: Ludolph
  fullname: Ludolph, Albert C.
  email: albert.ludolph@rku.de
  organization: German Center for Neurodegenerative Diseases, Ulm, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34457038$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhS1URB_wA9igSGzYpPiR2M4GCVUURhqJDayta8eZepTYg-2MNP--TqeFtgjkha3r75x7_DhHJz54i9Bbgi8JEeIjES2nkjeUEMww4-0LdLbU6qV48mh9is5T2mLMqWjwK3TKmqYVmMkztFoHv6mzjVOV5rh3exgr8DAekktVGKoJksvOO105X8F0CDmG3Y0z1QhFVOBkRhtDoV-jlwOMyb65ny_Qz-svP66-1evvX1dXn9e1aRnNtQZMtODAdIdx14IGKjAlpsSkwnLDMViQlA8c075rDB1wK3FvGHTa2qZjF2h19O0DbNUuugniQQVw6q4Q4kZBzK7EUoOQAJyWFhqXA_fStoPuAaQdSOneFK9PR6_drCfbG-tzOdMT06c73t2oTdgryaQkkheDD_cGMfyabcpqcsnYcQRvw5wUbTmny2AFff8M3YY5lqsuFCeMNoJzXKh3jxP9jvLwYgUQR8CUW0_RDsq4DNmFJaAbFcFq-Rvqr79RlOSZ8sH8f5rLoybBxv4J_G_BLQ3Cx64
CitedBy_id crossref_primary_10_1038_s41593_023_01323_6
crossref_primary_10_3390_ph16040615
crossref_primary_10_3390_biomedicines12061294
crossref_primary_10_1016_j_bmcl_2021_128482
crossref_primary_10_3390_biomedicines12102200
crossref_primary_10_3390_jpm12101601
crossref_primary_10_1186_s13023_024_03057_5
crossref_primary_10_1126_scitranslmed_adj9332
crossref_primary_10_17116_jnevro202412404113
crossref_primary_10_1186_s40478_021_01241_3
crossref_primary_10_4103_1673_5374_382226
crossref_primary_10_1212_NXI_0000000000200241
crossref_primary_10_20883_medical_e710
crossref_primary_10_1097_WCO_0000000000001279
crossref_primary_10_1007_s11011_023_01334_z
crossref_primary_10_1002_ana_27126
crossref_primary_10_1016_j_neurot_2024_e00469
crossref_primary_10_1016_S1474_4422_24_00326_0
crossref_primary_10_1186_s40035_023_00380_y
crossref_primary_10_1186_s12916_024_03293_3
crossref_primary_10_3389_fimmu_2023_1223096
crossref_primary_10_3390_ijms25052698
crossref_primary_10_1016_j_biopha_2023_114378
crossref_primary_10_1080_13543784_2023_2178416
crossref_primary_10_1002_med_22033
crossref_primary_10_3390_ph17101286
crossref_primary_10_3390_ijms25031751
crossref_primary_10_3389_fphar_2022_1054006
crossref_primary_10_1007_s40265_022_01769_1
crossref_primary_10_1007_s00018_024_05229_9
crossref_primary_10_14336_AD_2023_0519
crossref_primary_10_1007_s10072_023_07259_w
crossref_primary_10_1021_acs_chemrestox_2c00057
crossref_primary_10_1042_BST20230257
crossref_primary_10_1111_emre_12492
Cites_doi 10.1172/jci.insight.123249
10.1136/jnnp.2007.118018
10.1016/S1474-4422(17)30163-1
10.1016/S0140-6736(02)07882-0
10.1212/01.wnl.0000243812.25517.87
10.1002/glia.23768
10.1016/j.nbd.2020.105052
10.1016/S1474-4422(18)30176-5
10.1016/j.jclinepi.2010.07.017
10.1055/s-0030-1267080
10.1016/S1474-4422(14)70129-2
10.1016/S0140-6736(16)31403-9
10.1172/jci.insight.95934
10.1186/s40035-020-00221-2
10.3109/21678421.2015.1049183
10.1080/21678421.2019.1632346
10.1016/S1474-4422(17)30115-1
10.1212/01.wnl.0000194316.91908.8a
10.1212/WNL.0000000000007242
10.1136/jnnp-2015-310998
10.1002/ana.25661
10.1186/1745-6215-11-104
10.1186/s12974-016-0620-9
10.1016/j.jns.2008.07.016
ContentType Journal Article
Copyright The Author(s), 2021
The Author(s), 2021.
The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2021
– notice: The Author(s), 2021.
– notice: The Author(s), 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
NPM
3V.
7TK
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
7X8
5PM
DOA
DOI 10.1177/17562864211030365
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database (Proquest)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Psychology
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-2864
ExternalDocumentID oai_doaj_org_article_f78aa62ba2b0457d8e5fbdaa8ef19004
PMC8388186
34457038
10_1177_17562864211030365
10.1177_17562864211030365
Genre Journal Article
GroupedDBID ---
-TM
01A
0R~
123
18M
29Q
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AADUE
AAKDD
AAQDB
AARDL
AARIX
AASGM
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABNCE
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B8M
BAWUL
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
COF
CS3
DC-
DC.
DIK
DOPDO
E3Z
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
PSYQQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
31X
AADTT
AATBZ
ACGZU
ACSBE
ACSIQ
ACUIR
AEUIJ
AEWHI
B8Z
DV7
M4V
NPM
SGV
3V.
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c532t-ba01b76a3b90095aba27021c28627e6c60aea826f602d94c2f0580dc3a9bee493
IEDL.DBID DOA
ISSN 1756-2864
1756-2856
IngestDate Wed Aug 27 01:23:55 EDT 2025
Thu Aug 21 18:31:28 EDT 2025
Fri Sep 05 13:22:51 EDT 2025
Mon Jun 30 11:56:11 EDT 2025
Wed Feb 19 02:26:11 EST 2025
Thu Apr 24 23:03:34 EDT 2025
Sun Jul 06 05:06:18 EDT 2025
Tue Jun 17 22:26:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords clinical trials
masitinib
tyrosine kinase inhibitor
therapy
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
The Author(s), 2021.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c532t-ba01b76a3b90095aba27021c28627e6c60aea826f602d94c2f0580dc3a9bee493
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9175-5051
0000-0003-3127-7486
OpenAccessLink https://doaj.org/article/f78aa62ba2b0457d8e5fbdaa8ef19004
PMID 34457038
PQID 2613247660
PQPubID 4450847
ParticipantIDs doaj_primary_oai_doaj_org_article_f78aa62ba2b0457d8e5fbdaa8ef19004
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8388186
proquest_miscellaneous_2566262623
proquest_journals_2613247660
pubmed_primary_34457038
crossref_citationtrail_10_1177_17562864211030365
crossref_primary_10_1177_17562864211030365
sage_journals_10_1177_17562864211030365
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in neurological disorders
PublicationTitleAlternate Ther Adv Neurol Disord
PublicationYear 2021
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References Kwon, Koh 2020; 9
Lortholary, Chandesris, Livideanu 2017; 389
Mitsumoto, Brooks, Silani 2014; 13
Zoccolella, Beghi, Palagano 2008; 79
2017; 16
Kollewe, Mauss, Krampfl 2008; 275
Trias, Ibarburu, Barreto-Núñez 2017; 2
Whitfield, Huemer, Winter 2010; 11
Trias, Ibarburu, Barreto-Núñez 2016; 13
Schulz, Grimes 2002; 359
Guyatt, Oxman, Vist 2011; 64
Labra, Menon, Byth 2016; 87
Dettori 2011; 2
Hardiman, Van Den Berg 2017; 16
Trias, Kovacs, King 2020; 68
Ludolph, Dorst, Dreyhaupt 2020; 87
Ludolph, Schuster, Dorst 2018; 17
Gordon, Cheung 2006; 67
Van Den Berg, Sorensen, Gronseth 2019; 92
Trias, King, Si 2018; 3
Ludolph, Drory, Hardiman 2015; 16
Kimura, Fujimura, Ishida 2006; 66
Harrison, Rafuse 2020; 145
Mora, Genge, Chio 2020; 21
bibr20-17562864211030365
bibr8-17562864211030365
bibr23-17562864211030365
bibr10-17562864211030365
bibr26-17562864211030365
bibr13-17562864211030365
bibr16-17562864211030365
bibr19-17562864211030365
bibr6-17562864211030365
bibr3-17562864211030365
bibr1-17562864211030365
bibr4-17562864211030365
bibr14-17562864211030365
bibr24-17562864211030365
bibr27-17562864211030365
bibr17-17562864211030365
bibr7-17562864211030365
bibr11-17562864211030365
bibr21-17562864211030365
bibr9-17562864211030365
bibr12-17562864211030365
bibr25-17562864211030365
bibr18-17562864211030365
bibr2-17562864211030365
bibr28-17562864211030365
bibr15-17562864211030365
bibr5-17562864211030365
bibr22-17562864211030365
References_xml – volume: 11
  start-page: 104
  year: 2010
  article-title: Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries
  publication-title: Trials
– volume: 359
  start-page: 781
  year: 2002
  end-page: 785
  article-title: Sample size slippages in randomised trials: exclusions and the lost and wayward
  publication-title: Lancet
– volume: 92
  start-page: e1610
  year: 2019
  end-page: e1623
  article-title: Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
  publication-title: Neurology
– volume: 66
  start-page: 265
  year: 2006
  end-page: 267
  article-title: Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
  publication-title: Neurology
– volume: 2
  start-page: 7
  year: 2011
  end-page: 10
  article-title: Loss to follow-up
  publication-title: Evid Based Spine Care J
– volume: 16
  start-page: 291
  year: 2015
  end-page: 292
  article-title: A revision of the El Escorial criteria
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener
– volume: 2
  start-page: e95934
  year: 2017
  article-title: Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS
  publication-title: JCI Insight
– volume: 16
  start-page: 490
  year: 2017
  end-page: 491
  article-title: Edaravone: a new treatment for ALS on the horizon?
  publication-title: Lancet Neurol
– volume: 79
  start-page: 33
  year: 2008
  end-page: 37
  article-title: Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 16
  start-page: 505
  year: 2017
  end-page: 512
  article-title: ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized double-blind, placebo-controlled trial
  publication-title: Lancet Neurol
– volume: 3
  start-page: e123249
  year: 2018
  article-title: Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS
  publication-title: JCI Insight
– volume: 68
  start-page: 1165
  year: 2020
  end-page: 1181
  article-title: Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis
  publication-title: Glia
– volume: 87
  start-page: 628
  year: 2016
  end-page: 632
  article-title: Rate of disease progression: a prognostic biomarker in ALS
  publication-title: J Neurol Neurosurg Psychiatry
– volume: 13
  start-page: 1127
  year: 2014
  end-page: 1138
  article-title: Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
  publication-title: Lancet Neurol
– volume: 389
  start-page: 612
  year: 2017
  end-page: 620
  article-title: Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
  publication-title: Lancet
– volume: 21
  start-page: 5
  year: 2020
  end-page: 14
  article-title: Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised clinical trial
  publication-title: Amyotroph Lateral Scler Frontotemporal Degener
– volume: 67
  start-page: 1314
  year: 2006
  end-page: 1315
  article-title: Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
  publication-title: Neurology
– volume: 145
  start-page: 105052
  year: 2020
  article-title: Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice
  publication-title: Neurobiol Dis
– volume: 9
  start-page: 42
  year: 2020
  article-title: Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
  publication-title: Transl Neurodegener
– volume: 64
  start-page: 407
  year: 2011
  end-page: 415
  article-title: GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
  publication-title: J Clin Epidemiol
– volume: 13
  start-page: 177
  year: 2016
  article-title: Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
  publication-title: J Neuroinflammation
– volume: 17
  start-page: 681
  year: 2018
  end-page: 688
  article-title: Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
  publication-title: Lancet Neurol
– volume: 275
  start-page: 69
  year: 2008
  end-page: 73
  article-title: ALSFRS-R score and its ratio: a useful predictor for ALS-progression
  publication-title: J Neurol Sci
– volume: 87
  start-page: 206
  year: 2020
  end-page: 216
  article-title: Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis
  publication-title: Ann Neurol
– ident: bibr3-17562864211030365
  doi: 10.1172/jci.insight.123249
– ident: bibr23-17562864211030365
  doi: 10.1136/jnnp.2007.118018
– ident: bibr28-17562864211030365
  doi: 10.1016/S1474-4422(17)30163-1
– ident: bibr25-17562864211030365
  doi: 10.1016/S0140-6736(02)07882-0
– ident: bibr11-17562864211030365
  doi: 10.1212/01.wnl.0000243812.25517.87
– ident: bibr2-17562864211030365
  doi: 10.1002/glia.23768
– ident: bibr1-17562864211030365
  doi: 10.1016/j.nbd.2020.105052
– ident: bibr17-17562864211030365
  doi: 10.1016/S1474-4422(18)30176-5
– ident: bibr26-17562864211030365
  doi: 10.1016/j.jclinepi.2010.07.017
– ident: bibr24-17562864211030365
– ident: bibr27-17562864211030365
  doi: 10.1055/s-0030-1267080
– ident: bibr14-17562864211030365
  doi: 10.1016/S1474-4422(14)70129-2
– ident: bibr22-17562864211030365
  doi: 10.1016/S0140-6736(16)31403-9
– ident: bibr4-17562864211030365
  doi: 10.1172/jci.insight.95934
– ident: bibr20-17562864211030365
– ident: bibr7-17562864211030365
– ident: bibr19-17562864211030365
  doi: 10.1186/s40035-020-00221-2
– ident: bibr13-17562864211030365
  doi: 10.3109/21678421.2015.1049183
– ident: bibr15-17562864211030365
– ident: bibr6-17562864211030365
  doi: 10.1080/21678421.2019.1632346
– ident: bibr16-17562864211030365
  doi: 10.1016/S1474-4422(17)30115-1
– ident: bibr8-17562864211030365
  doi: 10.1212/01.wnl.0000194316.91908.8a
– ident: bibr12-17562864211030365
  doi: 10.1212/WNL.0000000000007242
– ident: bibr9-17562864211030365
  doi: 10.1136/jnnp-2015-310998
– ident: bibr18-17562864211030365
  doi: 10.1002/ana.25661
– ident: bibr21-17562864211030365
  doi: 10.1186/1745-6215-11-104
– ident: bibr5-17562864211030365
  doi: 10.1186/s12974-016-0620-9
– ident: bibr10-17562864211030365
  doi: 10.1016/j.jns.2008.07.016
SSID ssj0062740
Score 2.4168444
Snippet Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate...
A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional...
Background: A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 17562864211030365
SubjectTerms Amyotrophic lateral sclerosis
Oral administration
Original Research
Patients
Placebos
Survival
Survival analysis
SummonAdditionalLinks – databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0BPFF_L7qKREEQQh20zZNnkTF4xT1yYN9K_m8K-y163b3wf_emW62d8vp0T61aZl8TOaXzOQ3AG-0Uz4Ea1C_y4KjPS65Nlpzr4jrQ1fkDKJoi5_y5LT8Nq_macNtSGGVuzlxnKh972iP_D0ifbT9tZT5h-VvTlmjyLuaUmjchjszRCKUuqGeTwsuSiuzPRBZSS5UJZNXkwiX6JlQdMqT8mwVZFuu2KWRvv9fmPN66OSV-K_RJB0_gPsJS7KP285_CLdC9wju_kje8sfw9XvfnXGae9mwwSkBBxUziYSE9ZFdGArY6lrL2o6Ziz_9etUvz1vHFobOJS_YgL9FadvhCZwef_n1-YSn1AncVYVYc2vyma2lKawmEGWsoXNnM4dVFnWQTuYmGFxZRJkLr0snYl6p3LvCaBtCqYuncND1XTgEhjodETPJKtYeF5tRWR_QqIeIN8JznUG-a7jGJV5xSm-xaGaJSvxaW2fwbvpkuSXVuKnwJ-qNqSDxYY8P-tVZk9SribUyRgqspkWMWnsVqmi9MQrFxBYoMzja9WWTlHRoLodUBq-n16he5DMxXeg3WAbhrqCryODZtusnSYqyJP4ylUG9Nyj2RN1_07XnI4W3KhRRCWbwlobPpUj_bYXnN1fgBdwTFGwz7g0dwcF6tQkvES2t7atRJf4CVxoMVw
  priority: 102
  providerName: ProQuest
– databaseName: Sage Journals GOLD Open Access 2024
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-NTkK8oI2vBQYyEhISklmaOI79uKFVAwEPaBN7i2zH2SK1ydSmD_vvuUucQrWBUPuUuM3lfHf-ne_DAO-0U6X31qB-i5Tjeiy4NlrzUlGvD51RMIiyLb7Lswvx5TK73IF2rIUJHFx9pLQqpKg31qTdtBt9FIKMR7jmUUmlIO-FbDC69N2iGLa7x1M16ArFp9cLCm07Soi85WN52wPYTfJMJxPYPZ79-Hk-Gm86iWaoocwkpyeEQOi9D91ayvqO__fB1LvZln-kjPWr2GwPHgf4yY4HedmHHd88gYffQoD9KXz-2jZXnMw1W63RiqAcMhP6lrC2YgtDOV5NbVndMLO4bbtle3NdOzY3VMo8Zyv8W6S2Xj2Di9np-aczHk5b4C5Lk45bE09tLk1qNeEuYw2Vqk0dvnKSe-lkbLxBZ6SScVJq4ZIqzlRcutRo673Q6XOYNG3jD4ChGagQZsmsykv0TytlS484wFf4RUSvI4hHxhUutCKnEzHmxTR0H7_D6wg-bH5yM_Th-NfgE5qNzUBqod1faJdXRdDIosqVMTLB17QIa_NS-ayypTEKyUQOiAgOx7ksRqks0N9EBJpLGUfwdnMbNZLCLKbx7RrHIEJO6JNG8GKY-g0lqRDU8kxFkG8JxRap23ea-rrv-q1SRd0HI3hP4vObpL9y4eV_j3wFjxJK1el3lg5h0i3X_jVirc6-CfrxC2YdH_o
  priority: 102
  providerName: SAGE Publications
Title Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
URI https://journals.sagepub.com/doi/full/10.1177/17562864211030365
https://www.ncbi.nlm.nih.gov/pubmed/34457038
https://www.proquest.com/docview/2613247660
https://www.proquest.com/docview/2566262623
https://pubmed.ncbi.nlm.nih.gov/PMC8388186
https://doaj.org/article/f78aa62ba2b0457d8e5fbdaa8ef19004
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7SBEovpU1fbtNFhUKgYKr4occxKVmSkIYSErI3M7KlxrCxQ3b30H_fGdu7zZI-LsUHgyWb8WhG8401_gTw0Zam8t4h-XeWxhSPs9iitXFlmOvD5rwYxNUWZ-roMjuZ5JN7W31xTVhPD9wr7nPQBlElDhNH6ENXxufBVYjGB4plPROotHKZTPVzMG8os1zDZHolipH8C2bG2Q7P2flaFOrI-n-HMB8WSt6r9uoC0PgZPB2Qo9jvJX4OG77Zhsdfh7XxF3B82jbfY55pxWxBEwCZkMCBckS0Qdwgl2c1tRN1I_DmRzu_a2-v61JMkf9CnooZPZakrWcv4XJ8ePHlKB42SojLPE3msUO557TC1FmGTEjK0hS7S3rlRHtVKokeKY8ISiaVzcokyNzIqkzROu8zm76CzaZt_BsQ5MGBEJLKg64otQzGVZ5COCnbBwLjNgK5VFxRDizivJnFtNgbiMMf6DqCT6tbbnsKjb91PuDRWHVk9uvuAtlEMdhE8S-biGBnOZbF4JKzglJFAo9aKRnBh1UzOROvkGDj2wX1IXCb8JFG8Lof-pUkaZYxW5mJQK8ZxZqo6y1Nfd0RdpvUMHFgBLtsPr9E-qMW3v4PLbyDJwkX4HTfi3Zgc3638O8JQc3dCB7piR7B1v74_OqCzgeHZ9_OR50L_QS91xhV
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5VRQIuqLxDCxgJhIQUkXUcxzkgxKvapdueWmlvwY6dNtI2WTa7Qv1T_EZm8iqrQm_V5pQ4m4k9z8z4G4DXSaasc0ajfIvQR3ss_EQniW8VYX0kESWDqNriSI5PxPdZNNuC3_1eGCqr7HVio6htldE38vfo6aPtj6UMPi5--tQ1irKrfQuNli0O3MUvDNnqD5OvuL5vON__dvxl7HddBfwsCvnKNzoYmVjq0CTkX2ijaUvWKOPo28dOZjLQTqPTncuA20RkPA8iFdgs1IlxThD4Eqr8W4JSjCg_8WwI8KiNTbsBM5I-V5HssqgE8ETn8AmC4i2yGtGGHWzaBfzLx71aqvlXvVljAvd34F7nu7JPLbPdhy1XPoDbh112_iFMplV56pOuZ_UaVRAyMdMd6AmrcnauqUCsLAwrSqbPL6rVslqcFRmba9oHPWc1_i1SW9SP4ORGJvUxbJdV6Z4CQx2So48mozy2GNzmyliHToTL8cBwIPEg6CcuzTocc2qnMU9HHXT5lbn24N1wy6IF8bhu8GdajWEg4W83J6rladqJc5rHSmvJ8TUNskFslYtyY7VWSCbOgPBgr1_LtFMKdXrJwh68Gi6jOFOORpeuWuMYdK85_UIPnrRLP1ASCkF4acqDeIMpNkjdvFIWZw1kuAoVQRd68JbY55Kk_87Cs-tf4CXcGR8fTtPp5OhgF-5yKvRpvkvtwfZquXbP0VNbmReNeDD4cdPy-AfQREjK
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ra9RAEB_0CsUvUp-NrbqCIAixuTw2ux_r42i1FpEW-y3MZnfbwDU57vHB_96Z3N7p0SqSfEo2YTK788rM_Bbgta6Vdc4gyXeexWSP81ij1rFVjPWhC04GcbXFqTw6zz9fFBfhhxv3wgQOzt5xWRVR1Ctrlu6J9Qchx3hAJo87KnMOXlgFF3dhi8IalQxg63D0_cfZShfzxjLLlshCxvxEyGve-pINy9QD-N_mdd4snvyjAqw3SqMduB-8SXG4nP4HcMe1D2H7a8iXP4Ljk669jFn7itmClAItK4EBhkR0Xlwjl2y1jRFNK_D6ZzefdpOrphZj5M7ksZjRa4naZvYYzkefzj4cxWHzhLgusnQeG0yGppSYGc1uFBrkzrNhTZ-clk7WMkGHFFt4maRW53Xqk0Ilts5QG-dynT2BQdu1bhcESbUnr0kWvrQUbnplrCOz7jyd5KDrCJIV46o6IIvzBhfjahjAxG_wOoK360cmS1iNfw1-z7OxHsiI2P2FbnpZBQGrfKkQZUqfachLLa1yhTcWURGZxIE8gv3VXFarRVZR-EgOZSllEsGr9W0SMM6aYOu6BY0hhzflI4vg6XLq15Rkec4IZiqCcmNRbJC6eadtrnoQb5UpBhOM4A0vn98k_ZULz_575EvY_vZxVJ0cn37Zg3spF-H0_4z2YTCfLtxz8qLm5kUQlV8C_g5x
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+survival+analysis+of+masitinib+in+amyotrophic+lateral+sclerosis&rft.jtitle=Therapeutic+advances+in+neurological+disorders&rft.au=Mora%2C+Jesus+S.&rft.au=Bradley%2C+Walter+G.&rft.au=Chaverri%2C+Delia&rft.au=Hern%C3%A1ndez-Barral%2C+Mar%C3%ADa&rft.date=2021&rft.pub=SAGE+Publications&rft.issn=1756-2856&rft.eissn=1756-2864&rft.volume=14&rft_id=info:doi/10.1177%2F17562864211030365&rft_id=info%3Apmid%2F34457038&rft.externalDocID=PMC8388186
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-2864&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-2864&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-2864&client=summon